ALLERGY THERAPEUTICS PLC (NASDAQ:AGY ) Hardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth

Transparency directive : regulatory news

27/09/2018 08:15

01/07/2019 08:20
01/07/2019 08:15
21/05/2019 09:30
21/05/2019 08:15
18/03/2019 12:30
06/03/2019 13:10
17/01/2019 10:56
27/09/2018 08:15
13/07/2018 10:40
21/05/2018 13:25

Hardman & Co Research
Hardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth

27-Sep-2018 / 07:15 GMT/BST

Hardman & Co: 2018 full-year results: solid growth

AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a 'named-patient' basis. The Phase III trial, designed to obtain approval for PQ Birch as a biologic in Europe, is well advanced and will report data by the end of 2018. As discussed at the interim stage, underlying sales growth was affected by a low pollen season in central Europe. Full-year results suggest that this has remained a difficult market, but one in which AGY has continued to gain market share.Please click here for the full report:

To contact us:

Hardman & Co
35 New Broad Street
Follow us on Twitter @HardmanandCo

Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

+44 20 7194 7622

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

727781  27-Sep-2018